Close Menu

NEW YORK (GenomeWeb) – Biocept today announced that it has signed two new agreements with preferred provider organization networks — Fortified Provider Network and Three Rivers Provider Network.

Under the deals, the approximately 26 million members of these two PPOs will now have covered access to Biocept's Target Selector non-invasive liquid biopsy assays, which include tests for melanoma, breast, lung, and gastric cancer biomarkers.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Retraction Watch reports that a paper was pulled because it refers to a gene that doesn't exist in mice.

Researchers were able to generate fertilized northern white rhinoceros eggs, according to Mashable.

Former Orig3n employees raise concerns about its testing at Bloomberg Businessweek.

In PLOS this week: microRNA expression changes in hepatocellular carcinoma, real-time PCR-based approach for diagnosing schistosomiasis, and more.